Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Blankestijn, Peter"'
Autor:
Vervloet Marc G, van Zuilen Arjan D, Heijboer Annemieke C, ter Wee Piet M, Bots Michiel L, Blankestijn Peter J, Wetzels Jack FM
Publikováno v:
BMC Nephrology, Vol 13, Iss 1, p 20 (2012)
Abstract Background Fibroblast growth factor 23 (FGF23) has emerged as a risk factor for cardiovascular disease and mortality throughout all stages of chronic kidney disease (CKD), independent from established risk factors and markers of mineral home
Externí odkaz:
https://doaj.org/article/5589bcd356ac4bf78802666178685e05
Autor:
Vervoort Gerald, van de Ven Peter JG, Kaasjager Karin AH, ten Dam Marc AGJ, van Buren Marjolijn, Bots Michiel L, Blankestijn Peter J, van der Tweel Ingeborgh, van Zuilen Arjan D, Vleming Louis-Jean, Ligtenberg Gerry, Wetzels Jack FM
Publikováno v:
Trials, Vol 7, Iss 1, p 8 (2006)
Abstract Background Patients with chronic kidney disease (CKD) are at a greatly increased risk of developing cardiovascular disease. Recently developed guidelines address multiple risk factors and life-style interventions. However, in current practic
Externí odkaz:
https://doaj.org/article/414b9efcf6d44efb87d71339c0c8aa9b
Autor:
Nubé Menso J, Grooteman Muriel P, van den Dorpel Marinus A, Bots Michiel L, Blankestijn Peter J, Penne E Lars, van der Tweel Ingeborg, ter Wee Piet M
Publikováno v:
Current Controlled Trials in Cardiovascular Medicine, Vol 6, Iss 1, p 8 (2005)
Abstract Background The high incidence of cardiovascular disease in patients with end stage renal disease (ESRD) is related to the accumulation of uremic toxins in the middle and large-middle molecular weight range. As online hemodiafiltration (HDF)
Externí odkaz:
https://doaj.org/article/a8c79de19c6c4d41b320c12b8a50ae94